On May 19, 2020, ChromaCode, Inc., a company redefining molecular testing through data science, announced a $10 million Series C extension with an investment from Adjuvant Capital, which is backed by leading healthcare investors such as the Bill & Melinda Gates Foundation, the International Finance Corporation, and Novartis, bringing the company’s total Series C funding to $38 million. Adjuvant aims to drive meaningful improvements in the public health of low- and middle-income countries with a focus on neglected, high-burden and emerging infectious diseases, pandemic threats, and maternal and child health. Wilson Sonsini Goodrich & Rosati represented ChromaCode in the transaction.

Funding from the round will support global expansion and continued development of ChromaCode's high-definition PCR platform (HDPCR™), through which the company recently launched a high-throughput SARS-CoV-2 Assay. Adjuvant joins existing ChromaCode investors Northpond Ventures, New Enterprise Associates, Domain Associates, Windham Ventures, Okapi Ventures, Moore Venture Partners, and the California Institute of Technology.

The Wilson Sonsini team that represented ChromaCode in the funding transaction included Marty Waters. The team that represented the company in patent matters related to this transaction included Nicholas Tiee.

For more information, please see ChromaCode's press release.